Robert Schreiber, Ph.D., is the alumni endowed professor of pathology and immunology, professor of molecular microbiology, director of the Washington University Center for Human Immunology and Immunotherapy Programs, and co-leader of the tumor immunology program for the Siteman Comprehensive Cancer Center at Washington University. He is an associate director of the Cancer Research Institute, an affiliate of the Ludwig Institute for Cancer Research, a past member of the board of scientific advisors for the National Cancer Institute and a past president of the Society for Leukocyte Biology. Schreiber’s lab is highly regarded for its 35 years of research on the molecular cell biology and immunology of interferon-gamma and its receptor, as well as its strong expertise in mAb discovery. In addition, Schreiber and colleagues demonstrated that the unmanipulated immune system could eliminate spontaneous and carcinogen-induced primary tumors and thereby resolved the long-standing controversy over whether cancer immunosurveillance occurs. He also demonstrated that immunity can promote tumor dormancy and ultimately facilitate cancer progression by shaping tumor immunogenicity. These observations led Schreiber and colleagues to propose the concept of cancer immunoediting that has gained nearly universal acceptance in the last few years. Schreiber’s work has led to a generalized appreciation of the profound effect of immunity on developing tumors and has contributed critical conceptual and practical support to the fields of tumor immunology and cancer immunotherapy. Recently, Schreiber and colleagues pioneered the use of genomics approaches to define the antigenic targets of cancer immunoediting and elucidate the mechanisms that underlie the process. This latter work supports ongoing efforts to develop individualized cancer immunotherapies.
Schreiber has authored more than 300 peer reviewed and invited publications and has received several honors, including the Milstein Award for Outstanding Achievements in Research on Interferon and Cytokines from the International Society of Interferon and Cytokine Research, the Bonazinga Award for Excellence in Leukocyte Biology Research from the Society for Leukocyte Biology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the Cancer Research Institute, the Charles Rodolphe Brupbacher Award for Cancer Research from the Brupbacher Cancer Foundation in Switzerland, and the Lloyd J. Old Award for Cancer Immunology Research from the American Association for Cancer Research and the Cancer Research Institute. Schreiber is a member of the National Academy of Sciences, American Academy of Arts and Sciences, and a fellow of the American Association of Science. Dr. Schreiber holds a B.A. in chemistry and Ph.D. in biochemistry from the State University of New York at Buffalo.
Guoqing Chen, Ph.D. has extensive experience in antibody and small molecule drug discovery. He was formerly a Senior Scientist in the Department of Oncology at Amgen, where he led a multidisciplinary team to develop antibody-based therapeutics for cancer and a novel technology platform for antibody-directed delivery of cytotoxic drugs and siRNAs to tumor cells. Before joining Amgen, he was a Scientist at Tularik and completed postdoctoral studies under Dr. David Goeddel. Dr. Chen received his Ph.D. from UCLA.